SLS is trading 5.5% up today at $9.67 as traders continue positioning around binary Phase 3 REGAL trial results and elevated volatility typical for pre-readout biotech names.
- The price action follows a period of strong momentum and high short interest, though no fresh company-specific news or filings have emerged to directly explain today's move.
- Investors are navigating typical pre-readout volatility and profit-taking swings as anticipation builds for the pivotal data release.